Page 2 - Laurus Lab News Today

“We are very, very positive on the CDMO and CRO space within pharma, which we think is a very structural trend over the next 5 to 10 to 15 years. The CDMO space is a very small space right now. But what we saw in IT, we could see in the CDMO space, specific to pharma.”

“If you are betting into the jewellery sector, the period between Dhuleti and Dhanteras is the best time to accumulate these particular stocks and the moment the festive season starts, that is the best time to book some profit. That is how one can make maximum gain in this kind of business.”

Motilal Oswal is bullish on Laurus Labs recommended buy rating on the stock with a target price of Rs 460 in its research report dated October 20, 2023.

Banking remains the hot favourite among fund managers and that seems to be part of the problem. If most people have already become believers of the story, finding new faithfuls or converts becomes a tough task

“There is going to be a capital infusion of about Rs 20,000 to 22,000 crore in Indiabulls. And that would be at a significant premium and will be book value accretive. Post that, once there is a clean management and a substantial capital, they have a very decent book size.”

Biggest losers on the Nifty were Hero MotoCorp, Tata Motors, Tata Steel, NTPC and Eicher Motors, while gainers were Divis Labs, Nestle India, HUL and Asian Paints

Sector rotation is evident. But stock-specific rally will still continue. I do not think that bull market has ended.

Laurus Labs Q1 consolidated net profit fell 90% YoY to INR25 crore due to lower sales and elevated expenses. The API business reported a 2% growth in revenues to INR597 crore, however, sequentially it experienced a 16% decline. Indian Energy Exchange recorded a 10% YoY rise in consolidated

To hold 33.86% stake post-completion of the transaction

Company in the quarter ended March 2023 reported 55.3 percent fall in its Q4FY23 net profit at Rs 102.98 crore against Rs 230.50 crore in March 2022.